Expression of Interferon Regulatory Factor 4 in Chronic Myeloid Leukemia

• Verfasst von: Schmidt, Manuel [VerfasserIn]
• Verfasst von: Hochhaus, Andreas [VerfasserIn]
• Verfasst von: König-Merediz, Sven A. [VerfasserIn]
• Verfasst von: Brendel, Cornelia [VerfasserIn]
• Verfasst von: Proba, Jutta [VerfasserIn]
• Verfasst von: Hoppe, Georg J. [VerfasserIn]
• Verfasst von: Wittig, Burghardt [VerfasserIn]
• Verfasst von: Ehninger, Gerhard [VerfasserIn]
• Verfasst von: Hehlmann, Rüdiger [VerfasserIn]
• Verfasst von: Neubauer, Andreas [VerfasserIn]
• Titel: Expression of Interferon Regulatory Factor 4 in Chronic Myeloid Leukemia
• Titelzusatz: Correlation With Response to Interferon Alfa Therapy
• Verf.angabe: Manuel Schmidt, Andreas Hochhaus, Sven A. König-Merediz, Cornelia Brendel, Jutta Proba, Georg J. Hoppe, Burghardt Wittig, Gerhard Ehninger, Rüdiger Hehlmann, Andreas Neubauer
• Jahr: 2000
• Fussnoten: Gesehen am 13.04.2022
• Titel Quelle: Enthalten in: Journal of clinical oncology
• Ort Quelle: Alexandria, Va. : American Society of Clinical Oncology, 1983
• Jahr Quelle: 2000
• Band/Heft Quelle: 18(2000), 19, Seite 3331-3338
• ISSN Quelle: 1527-7755
• DOI: doi:10.1200/JCO.2000.18.19.3331
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1799542645

Abstract

PURPOSE: Mice experiments have established an important role for interferon regulatory factor (IRF) family members in hematopoiesis. We wanted to study the expression of interferon regulatory factor 4 (IRF4) in various hematologic disorders, especially chronic myeloid leukemia (CML), and its association with response to interferon alfa (IFN-α) treatment in CML. - - MATERIALS AND METHODS: Blood samples from various hematopoietic cell lines, different leukemia patients (70 CML, 29 acute myeloid leukemia [AML], 10 chronic myelomonocytic leukemia [CMMoL], 10 acute lymphoblastic leukemia, and 10 chronic lymphoid leukemia patients), and 33 healthy volunteers were monitored for IRF4 expression by reverse transcriptase polymerase chain reaction. Then, with a focus on CML, the IRF4 level was determined in sorted cell subpopulations from CML patients and healthy volunteers and in in vitro-stimulated CML cells. Furthermore, IRF4 expression was compared in the CML samples taken before IFN-α therapy and in 47 additional CML samples taken during IFN-α therapy. IRF4 expression was then correlated with cytogenetic response to IFN-α. - - RESULTS: IRF4 expression was significantly impaired in CML, AML, and CMMoL samples. The downregulation of IRF4 in CML samples was predominantly found in T cells. In CML patients during IFN-α therapy, a significant increase in IRF4 levels was detected, and this was also observed in sorted T cells from CML patients. The increase seen during IFN-α therapy was not due to different blood counts. In regard to the cytogenetic response with IFN-α, a good response was associated with high IRF4 expression. - - CONCLUSION: IRF4 expression is downregulated in T cells of CML patients, and its increase is associated with a good response to IFN-α therapy. These data suggest IRF4 expression as a useful marker to monitor, if not predict, response to IFN-α in CML.